Blueprint Medicines Corporation (BPMC): Price and Financial Metrics

Blueprint Medicines Corporation (BPMC): $104.74

0.81 (-0.77%)

POWR Rating

Component Grades








Add BPMC to Watchlist
Sign Up

Industry: Biotech




#140 of 351

in industry

BPMC Price/Volume Stats

Current price $104.74 52-week high $111.02
Prev. close $105.55 52-week low $43.89
Day low $104.63 Volume 54,777
Day high $105.73 Avg. volume 706,872
50-day MA $99.91 Dividend yield N/A
200-day MA $79.20 Market Cap 6.56B

BPMC Stock Price Chart Interactive Chart >

Blueprint Medicines Corporation (BPMC) Company Bio

Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts.

BPMC Latest News Stream

Event/Time News Detail
Loading, please wait...

BPMC Latest Social Stream

Loading social stream, please wait...

View Full BPMC Social Stream

Latest BPMC News From Around the Web

Below are the latest news stories about BLUEPRINT MEDICINES CORP that investors may wish to consider to help them evaluate BPMC as an investment opportunity.

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 10:30 a.m. PT (1:30 p.m. ET).

Yahoo | December 18, 2023

Blueprint Medicines Corporation's (NASDAQ:BPMC) 38% Price Boost Is Out Of Tune With Revenues

Blueprint Medicines Corporation ( NASDAQ:BPMC ) shares have continued their recent momentum with a 38% gain in the last...

Yahoo | December 18, 2023

Insider Sell: Director Jeffrey Albers Sells 5,000 Shares of Blueprint Medicines Corp (BPMC)

Blueprint Medicines Corp (NASDAQ:BPMC) has recently witnessed a notable insider sell by Director Jeffrey Albers, who disposed of 5,000 shares of the company's stock.

Yahoo | December 14, 2023

Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. | December 13, 2023

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.

Yahoo | December 12, 2023

Read More 'BPMC' Stories Here

BPMC Price Returns

1-mo -0.21%
3-mo 19.06%
6-mo 24.51%
1-year 70.84%
3-year 26.51%
5-year 8.24%
YTD 13.55%
2023 110.55%
2022 -59.10%
2021 -4.49%
2020 40.00%
2019 48.60%

Continue Researching BPMC

Want to see what other sources are saying about Blueprint Medicines Corp's financials and stock price? Try the links below:

Blueprint Medicines Corp (BPMC) Stock Price | Nasdaq
Blueprint Medicines Corp (BPMC) Stock Quote, History and News - Yahoo Finance
Blueprint Medicines Corp (BPMC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!